Results 161 to 170 of about 86,846 (266)

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

Advanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao, Dongdong Liu, Haishan Gao, Chenyang Qin, Wen Zhang, Ziyun Lu, Dongxia Tan, Yuxiu Qu, Yusong Liu, Zhiran Zou, Hongtao Yu, Wei Qi   +11 more
wiley   +1 more source

Immune checkpoint blockade in cancer: current insights and future horizons. [PDF]

Discov Oncol
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, AbuHaweeleh MN, Abuhayeh N, Ismail MA, Prabhu KS, Fernandes Q, Jabi T, Elhussein R, Inchakalody VP, Merhi M, Dermime S, Uddin S.   +14 more
europepmc   +1 more source

Pharmacological Inhibition of FKBP51 Mitigates Early Life Adversity‐Induced Social Deficits in Male Mice

Advanced Science, EarlyView.
Early life adversity triggers persistent social subordination and brain‐wide molecular dysregulation. Pharmacological inhibition of the stress‐mediator FKBP51 during the adversity period prevents these long‐term deficits and restores normative social hierarchy.
Joeri Bordes, Xiuqi Ji, Serena Gasperoni, Choham Sudre‐Chinsky, Amirali Kalbasi, Daniela Harbich, Cornelia Flachskamm, Paula Fontanet, Sowmya Narayan, Manfred Uhr, Christian Namendorf, Camilla Bellone, Alon Chen, Felix Hausch, Juan Pablo Lopez, Mathias V. Schmidt   +15 more
wiley   +1 more source

Pharmacologic targeting of the dopamine D2 receptor impacts the efficacy of immune checkpoint blockade in melanoma. [PDF]

J Immunother Cancer
Gregory M, Hackett JB, Hughes S, Muñiz MC, Ayoub S, Boerner A, Alrabaa H, Taylor L, Rivera B, Holland H, Dyson G, Daveluy S, Gibson H.   +12 more
europepmc   +1 more source

Targeting DNGR‐1 with Fangchinoline Elevates Dendritic Cell Antigen Cross‐Presentation‐Mediated Antitumor Immunity in Melanoma

Advanced Science, EarlyView.
Fangchinoline is identified as a small‐molecule DNGR‐1 modulator that enhances dendritic‐cell cross‐presentation of tumor antigens. By engaging DNGR‐1 and activating Syk–Nox2 signaling, it promotes phagosomal ROS, antigen escape, MHC‐I presentation, and CD8+ T‐cell priming, thereby strengthening antitumor immunity and sensitizing tumors to PD‐1 ...
Yuan Liao, Zhenyang Ren, Jing Zhou, He Luo, Yuling Li, Dan Chen, Yuxiao Jiang, Canzhe Li, Mengyi Zheng, Anqi Li, Yao Wang, Yang Zhang, Dingye Wang, Yanjun Jiang, Jiangyong Gu, Biaoyan Du, Yafei Shi, Fang Liu, Jianyong Xiao, Kun Wang   +19 more
wiley   +1 more source

Amendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. [PDF]

J Clin Invest
Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y, Li Y, Wan C, So KM, Liu D, Frieden M, Fang Y, Mosley AL, He X, Zhang X, Sandusky GE, Liu Y, Meroueh SO, Zhang C, Wijeratne AB, Huang C, Ji G, Lu X.   +22 more
europepmc   +1 more source

All‐Flex Plasma Patch for In Vivo Delivery of Reactive Species

Advanced Science, EarlyView.
A fully flexible plasma patch enables stable, conformal treatment on complex biological surfaces and enhances transdermal delivery of reactive species. This platform achieves significant tumor suppression in vivo and reveals coordinated regulation of calcium signaling, metabolism, and programmed cell death, providing a promising strategy for safe and ...
Luxiang Zhao, Abulaihaiti Tuergong, Hanshu Yang, Shuang Xue, An Yan, Mingzhen Wang, Weilong Song, Wenzhe Si, Ruixue Wang   +8 more
wiley   +1 more source

Deciphering the mechanistic landscape of immune checkpoint blockade in ccRCC: from molecular drivers to therapeutic responses. [PDF]

Front Immunol
Ran L, Hu G, Fan C, Teng Y, Zhao R, Li Q, Yang JM, Zhang C.   +7 more
europepmc   +1 more source

Placental Site Trophoblastic Tumor Acquires Immune Functions by Incorporating Host Maternal Genes

Advanced Science, EarlyView.
PSTT cells, through cell fusion with B cells, incorporate abundant non‐inherited maternal genes that are detectable by DNIMA. These hybrid cells acquire immunotherapy‐resistant genetic changes and increase the expression of B cell‐derived immune‐related molecules such as Ig, HLA, LILRB, SIGLEC10, and so on, creating an immunotolerant environment around
Kyosuke Kagami, Masanori Ono, Yasunari Mizumoto, Tatsuhito Kanda, Takashi Iizuka, Takiko Daikoku, Shin‐ichi Horike, Akira Hattori, Akihito Horie, Sachiko Minamiguchi, Tomoko Fujiwara, Kazuyoshi Hosomichi, Atsushi Tajima, Hirokazu Usui, Kaoru Abiko, Hiroshi Fujiwara   +15 more
wiley   +1 more source

YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas. [PDF]

Neuro Oncol
Ali H, Zhou N, Chen L, van Hijfte L, Tulaiha R, Karri V, Zhou Y, Habashy K, Arrieta VA, Kim KS, Duffy J, Yeeravalli R, Tiek DM, Song X, Mishra S, Horbinski C, Lee-Chang C, Ahmed A, Wang L, Heiland DH, Sonabend AM, Dmello C.   +21 more
europepmc   +1 more source